GlobeNewswire Inc.
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
Rapport Therapeutics announced positive Phase 2 trial results for RAP-219 in treating acute bipolar mania, meeting primary and secondary endpoints with statistically significant placebo-adjusted improvements in YMRS scores (3.1 points, p=0.045) and CGI-BP mania severity (0.4 points, p=0.024). The drug demonstrated favorable tolerability with no severe adverse events, establishing clinical proof-of-concept for its novel TARPγ8-selective mechanism. Phase 3 trials are expected to begin in the second half of 2027.